glp-1/glucagon dual receptor agonist Schematic illustration of monoagonists, agonists and triple Discovery of Biased Dual-Agonists of

Exceptional safety margin No dependence or tolerance naturally occurring endogenous peptide Tolerability in clinical trials No tolerance develops with repeated doses No withdrawal symptoms upon stopping Peptide naturally present in the human body Research considerations Researcher's notes Outstanding safety profile for a bioactive peptide No serious adverse events were reported in the published studies

Risk factors for GD include genetic predisposition, environmental factors, and immunological factors (4)

VCAM-1, vascular cell adhesion molecule 1

The key mechanism for this seems to be renal re-absorption that displays saturation kinetics